Beovu(brolucizumab)
Beovu (brolucizumab) is an antibody pharmaceutical. Brolucizumab was first approved as Beovu on 2019-10-07. It is used to treat wet macular degeneration in the USA. It has been approved in Europe to treat wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A, long form. In addition, it is known to target Vascular permeability factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Beovu
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| beovu | Biologic Licensing Application | 2024-11-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| wet macular degeneration | EFO_0004683 | D057135 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0179 | Injection, brolucizumab-dbll, 1 mg |
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | 4 | 13 | 6 | 19 | 42 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | 1 | 4 | 10 | 5 | 6 | 25 |
| Macular edema | D008269 | — | — | — | — | 8 | 1 | 3 | 12 |
| Edema | D004487 | HP_0000969 | R60.9 | — | — | 6 | 1 | 2 | 9 |
| Retinal dystrophies | D058499 | HP_0000556 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vision disorders | D014786 | HP_0000505 | H53.11 | — | — | 7 | — | 1 | 8 |
| Low vision | D015354 | — | — | — | — | 7 | — | 1 | 8 |
| Choroidal neovascularization | D020256 | — | — | — | — | 2 | — | 2 | 4 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | 2 | — | — | 2 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | 2 | — | — | 2 |
| Pathologic neovascularization | D009389 | — | — | — | — | 2 | — | — | 2 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | 1 | — | — | 1 |
| Retinal degeneration | D012162 | HP_0001105 | — | — | — | 1 | — | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | 1 | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 1 | 1 |
| Uveitis | D014605 | HP_0000554 | H20.9 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Retinal artery occlusion | D015356 | EFO_1001154 | H34.1 | — | — | — | — | 1 | 1 |
| Vasculitis | D014657 | HP_0002633 | — | — | — | — | — | 1 | 1 |
| Retinal vasculitis | D031300 | EFO_1001156 | H35.06 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Brolucizumab |
| INN | brolucizumab |
| Description | Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707357 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14864 |
| UNII ID | XSZ53G39H5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Beovu – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,057 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,144 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use